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Reactive oxygen species play an important role in the process of apoptosis in many cell types. In this paper, we analyzed the
role of ROS in DNA-damaging agents (actinomycin D or decitabine), which induced apoptosis of leukemia cell line CML-T1
and normal peripheral blood lymphocytes (PBL). The possibility of synergism with histone deacetylase inhibitors butyrate or
SAHA is also reported. We found that in cancer cell line, ROS production signiﬁcantly contributed to apoptosis triggering, while
in normal lymphocytes treated by cytostatic or cytotoxic drugs, necrosis as well as apoptosis occurred and large heterogeneity
of ROS production was measured. Combined treatment with histone deacetylase inhibitor did not potentiate actinomycin D
action, whereas combination of decitabine and SAHA brought synergistic ROS generation and apoptotic features in CML cell line.
Appropriate decrease of cell viability indicated promising therapeutic potential of this combination in CML, but side eﬀects on
normal PBL should be taken into attention.
1.Introduction
Increased caspase-dependent apoptosis, reactive oxygen spe-
cies (ROS) generation and mitochondrial damage are phe-
nomena, which can be frequently observed altogether in cells
subjected to anticancer drugs treatment, that is, accumu-
lation of ROS inside the cell often signalizes apoptosis or
terminaldiﬀerentiation[1].Ontheotherhand,interleukins-
(IL-7- and IL-3-) induced ROS generation provides cell
survival [2, 3]. Among the agents upregulating ROS, we can
ﬁnd natural compounds (EGCG, curcumin, or garlic [4–6]),
anti-inﬂammatory agents (parthenolide, quercetin [7, 8]),
anticancer chemical drugs (paclitaxel, cisplatin, doxorubicin
[9–11]), and even some antioxidants (e.g., melatonin [12]).
Some of the ROS inductions correlate with apoptosis [13],
other occur as independent phenomena [14]. In many
cases, potentiation of another drug action or sensitization of
resisting cells is induced by ROS generation [4, 15–18].
Along with ROS generation, DNA damage has usually
been observed during the process of cell death. These two
phenomena, the increase of ROS level and DNA damage, can
befoundeitherindependentoronebeingcausedbytheother
one. Actinomycin D (Dactinomycin, actD) causes breaks in
both ds and ssDNA, and cells treated by actinomycin D
are reported to be more sensitive to subsequent treatment
(TRAIL, TNF-alpha) because of elevating reactive oxygen
speciesconcentration[18,19].DNA-damagecausedbyhigh-
concentration of 5-aza-2 deoxycytidine (decitabine, DAC)
was reported to be accompanied by caspase-independent
ROS generation in myeloma cells [20]a sw e l la sb yR O S
production-dependent apoptosis in p53-mutant leukemic T-
cells [21]. No eﬀect on ROS production in normal peripheral
blood lymphocytes was detected [22]. At low concentrations,
(up to 1μM) DAC acts as S-phase-speciﬁc epigenetic agent
(DNA-methyltransferase inhibitor) causing de novo DNA
hypermethylation and silencing of transcription process.
This fact is now widely exploited in new therapeutic strate-
gies [23, 24]. Nevertheless, our experiments are focused on
the DNA-damaging eﬀect of DAC occurring at high con-
centration treatment. Both of these drugs, actD and DAC,2 Oxidative Medicine and Cellular Longevity
are able to induce p53-dependent, mitochondria uncoupling
way of apoptosis in leukemia cell line CML-T1, but the
apoptosis is induced also in normal lymphocytes [22, 25].
Butyrate (BUT, in form of sodium butyrate), a short-
chain fatty acid and natural histone deacetylase inhibitor, is
known to induce terminal cell diﬀerentiation in HL-60 cells
[26]. Physiological concentrations of butyrate induce ROS
that transiently alter intracellular redox balance of intestinal
cells [27], preincubation by butyrate protects colonocytes
against H2O2-induced damage [28]. In normal peripheral
blood lymphocytes, butyrate induces apoptosis, which is
partly mediated by ROS [29]. Another histone deacety-
lase inhibitor, suberoylanilide hydroxamic acid (Vorinostat,
SAHA), increased reactive oxygen species levels in gastroin-
testinal tumor cells [30]a sw e l la si nl e u k e m i a[ 31]o rs m a l l
cell lung cancer cells [32]. These facts together with relatively
high resistance of normal cells to SAHA treatment [33, 34]
drift this drug to the forefront in anticancer research.
In this paper, we analyze the role of ROS in apoptosis
of leukemia cell line CML-T1 and normal peripheral blood
lymphocytes (PBL) induced by DNA-damaging agents, actD
or DAC, and by histone deacetylase inhibitor, BUT or SAHA.
Comparison with eﬀects induced by drug combinations is
also reported.
2.MaterialandMethods
2.1. Cell Culture. Human peripheral blood lymphocytes
of healthy donors were isolated from buﬀy coats using
density gradient centrifugation on Histopaque 1077 (Sigma-
Aldrich Corporation, St. Louis, MO, USA) at 500g and
20◦C for 25min. Histopaque-concentrated layer was resus-
pended in RPMI 1640 (Biochrom AG, Germany) for 45min
and monocytes were depleted by harvesting nonadherent
cells. Lymphocytes were resuspended at a density of 1 ×
106 cells/mLinRPMI1640medium(10%FCS,1%penicillin
+ streptomycin). CML-T1 cells were cultured in RPMI
1640 at starting density of 5 × 105 cells/mL. Actinomycin
D, Sodium Butyrate (both from Sigma-Aldrich), SAHA
(Cayman Chemical Company, Ann Arbor, MI, USA), and
Decitabine (Sigma-Aldrich) were added separately or in
combinations (concurrently) for time periods from 0 up to
48h (CML-T1) or 72h (PBL) at 37◦Ci n5 %C O 2.C o n c e n -
trations used for each cell type are indicated in Table 1.
2.2. Flow Cytometry. Cell viability (monitored by propid-
ium iodide, PI), generation of reactive oxygen species
(ROS, observed by dichlorodihydroﬂuorescein diacetate,
H2DCFDA), and mitochondrial membrane potential (MMP,
measured by MitoTracker Red, MTR) were investigated
by ﬂow cytometry. All ﬂuorescent probes were purchased
from Invitrogen (Carlsbad, CA, USA). Treated cells (2 ×
106 for CML, 1 × 107 for PBMC) were harvested,
washed with PBS, and suspended in 1mL PBS. H2DCFDA
or MTR was added to ﬁnal concentration of 10μM
(H2DCFDA) or 40nM (MTR) for 30min in 5% CO2 at
37◦C. After washing and resuspending the cells in PBS,
Table 1: Concentrations of drugs used for treatment of each cell
type.
Actinomycin D Sodium butyrate SAHA Decitabine
CML-T1 5nM 2mM 1μM8 μM
PBL 10nM 2mM 2μM8 μM
samples (50000events/sample) were analyzed on a FAC-
SCalibur Flow Cytometer (BD Biosciences, San Jose, CA,
USA). Ground level of ROS production was established
as H2DCFDA ﬂuorescence intensity reached by 50% of
untreatedcells.Regionofviablecellswasdeﬁnedassucharea
in scattergram, which was stable for all cell samples, and the
shift of H2DCFDA spectra was quantiﬁed as a proportion of
cells reaching ﬂuorescence intensity above the ground level.
I nd i a g r a m sa r i t h m e t i cm e a n so fa tl e a s tf o u rt i m e sr e p e a t e d
experiments were plotted with SEM error bars. Signiﬁcance
levels (P values of ANOVA analyses) were determined using
InStat Software (GraphPad Software). A P value of 0,05 or
lowerwasconsideredtobeastatisticallysigniﬁcantdiﬀerence
between the groups compared. The extent of mitochondria
staining by MitoTracker Red redistribution probe was inves-
tigated in order to observe mitochondrial membrane poten-
tial changes during cell exposure to diﬀerent drugs. Fluo-
rescence intensity threshold of polarized mitochondria was
deﬁned as a minimal intensity reached by MTR-stained
untreated cells. Proportion of cells with polarized mitochon-
dria (i.e., cells reaching the ﬂuorescence intensity threshold)
from each sample was calculated and used as a marker of
apoptosis. For PI-staining, 2μL of 250μg/mL propidium
iodide stock solution were added to 0,5mL of PBS-washed
cell suspension just before measurement. Fraction of living
cells was then deﬁned as an amount of PI-negative stained
cells.
2.3. Immunoblotting. Cells were cultured for intervals up to
44h (CML-T1) or 72h (PBL) in the absence or presence
of DNA-damaging agent (actinomycin D or decitabine)
and/or histone deacetylase inhibitor (sodium butyrate or
SAHA), harvested from cultures, washed in PBS, and then
b o i l e df o r5 m i ni n2 0 0 μl of Laemmli buﬀer. After cen-
trifugation at 200,000g and 4◦C for 3h, the supernatants
were subjected to 12% SDS PAGE electrophoresis and the
separated proteins were semidry blotted onto PVDF transfer
membranes (Amersham Biosciences, Piscataway, NJ, USA).
To measure PARP, β-actin, and capase 3 expression levels,
b l o t sw e r ed e v e l o p e da sd e s c r i b e dp r e v i o u s l y[ 25]. Brieﬂy,
membranes were blocked with 5% nonfat dried milk in
PBS/Tween and primary antibodies were added overnight
withaﬁnaldilutionrangeof1:500to1:2000.Afterwashing,
Pierce’s HRP-conjugated secondary antibodies (1:20,000–
1:100,000) were added for 2h (Pierce Biotechnology, Inc.
Rockford, IL, USA). Finally the blots were visualized using
the ECL Plus chemiluminescent substrate and ECL Hyper-
ﬁlmTM (both from Amersham). Signals were quantiﬁed
using the Power Look III scanner (UMAX Technologies, Inc.
Dallas, TX, USA) and image analyzer Software AIDA 1D. β-
actin expression served as a loading control. Primary rabbitOxidative Medicine and Cellular Longevity 3
polyclonal anti-PARP and mouse monoclonal anti-caspase 3
were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA,
USA), mouse monoclonal anti-β-actin was originated from
Sigma-Aldrich.
3. Results
3.1. Cell Viability. Viability of the CML-T1 (CML) cells and
normal peripheral blood lymphocytes (PBL) after treatment
with DNA-damaging drugs (actD or DAC), histone deacety-
lase inhibitors (BUT or SAHA), and their combinations was
assessed (Figure 1).
Concentrations of particular drugs were experimentally
determined to reach a similar eﬀect for both cell types.
Therefore,actDandSAHAconcentrationsforPBLtreatment
were doubled in comparison with concentrations used for
CML, while BUT and DAC were identical for CML and PBL.
Even these corrections did not erase the diﬀerence between
actD action on CML and PBL. In CML, actD caused more
than 50% viability drop, and addition of histone deacetylase
inhibitor (mostly non-toxic when applied alone) shortened
the phase of relative cell resistance from 24h to 16h. Only
moderate DAC individual action was strongly potentiated
by SAHA addition, namely, at 48h exposure. ActD was
substantially less toxic for PBL and HDACi addition had
almost no eﬀect on PBL viability. However, SAHA poten-
tiation of decitabine toxicity was observed in PBL too. In
conclusion, viability curves of combined treatment indicate
the possibility of DAC + SAHA synergism in CML as well as
in PBL.
3.2. ROS Generation. Generation of reactive oxygen species
in cells was monitored during the treatment with diﬀerent
drugsortheircombinations(Figure 2).Pvaluesofindividual
drugs action statistics and signiﬁcance of combined treat-
ments eﬀects are summarized in Table 2.
In CML cells, ROS production was lowered at initial 16h
and reached its original level after 24h of actD action, whilst
ROS concentration was substantially increased as compared
with control cells 48h after actD addition. Transient drop
of ROS concentration was observed also in cells treated by
DAC, but ensuing increase of ROS production was not large
enough to reach the initial concentration. BUT or SAHA
treatment brought gradual increase of ROS production in
CML. Combination of actD with any histone deacetylase
inhibitorresultedmostlyinsligtlyenhancedROSproduction
incomparisonwithHDACionly-inducedROS,irrespectively
to relevant ROS level generated by actD alone. Similarly,
DAC reduced ROS level when it was used as single agent,
but DAC + SAHA combination enhanced ROS generation in
comparison with action of SAHA alone.
In PBL, actD or DAC treatment caused only small
ﬂuctuations of ROS production over the control levels.
Histone deacetylase inhibitors induced ROS accumulation
alike in CML cells, but the data sets obtained from diﬀerent
buﬀy coats were largely dispersed. Almost no potentiating
eﬀects were detected when combinations with actD were
tested. Contrary to CML, even combination of DAC with
Table 2:(a)Pvaluesofone-wayANOVAofindividualdrugsaction.
(b) P values of “drug” parameter of two-way ANOVA for combined
treatments.
(a)
Cell type CML-T1 PBL
Drug
Actinomycin D <0,0001 0,12
Sodium butyrate 0,03 0,38
SAHA 0,003 0,08
Decitabine 0,16 0,34
(b)
Cell type CML-T1 PBL
Combination
ActD + BUT 0,03 0,74
ActD + SAHA 0,04 0,74
DAC + SAHA 0,003 0,52
SAHA was not synergistic in PBL from the ROS production
aspect.
3.3. Features of Apoptosis. PARP fragmentation and caspase
3 activation were monitored along with ROS production
measurements; representative immunoblots after 24h treat-
ment are shown in Figure 3. In accordance with viability
measurements, actD caused PARP fragmentation referring
considerablecellinjury,whileonlymoderatePARPfragmen-
tation was induced by DAC in both types of cells. Eﬀect
of histone deacetylase inhibitors diﬀered by HDACi, while
signiﬁcant PARP fragmentation is caused by SAHA, after
sodium butyrate exposure PARP fragmentation was only
weak. Herein, some potentiating eﬀect brought all the com-
binations tested. In contrast to these results, large caspase
3 activation was only detected for CML cells. According to
the PARP fragmentation characteristics, signiﬁcant executive
caspase activation was observed mainly in CML cells treated
by actD—either alone or in combinations—and also in
experiments with DAC + SAHA combination.
Figure 4 shows changes of another marker of intrinsic
apoptosis pathway, mitochondrial membrane potential, in
response to 24h treatment by individual drugs or by their
combinations. Consistently with foregoing results, no poten-
tiationofmitochondrialmembranedepolarizationcausedby
HDACi in combination with actD was possible to observe
in CML-T1 cells. Only weak eﬀect had all the drugs and
theircombinationsonmitochondrialmembranepotentialof
normal PBL after 24h of action.
4. Discussion
Apoptosis is a physiological process in normal cells and an
invalid apoptosis pathway has often been one of the main
hallmarks of cancer cells. Therefore, large attention is paid
to processes leading to changes in apoptosis. ROS formation
frequently occurs in the course of apoptotic process and its
contribution to programmed cell death is unquestionable.4 Oxidative Medicine and Cellular Longevity
CML-T1
0 10 20 30 40 50 60
100
80
60
40
A
B
S
D
AB
AS
DS
Time (h)
V
i
a
b
i
l
i
t
y
(
%
)
(a)
0 10 20 30 40 50 60 70 80
100
80
60
40
Time (h)
V
i
a
b
i
l
i
t
y
(
%
)
PBL
A
B
S
D
AB
AS
DS
(b)
Figure 1: Cell viability assessment in CML cells (a) and PBL (b) treated by actinomycin D (A), sodium butyrate (B), SAHA (S), decitabine
(D) or their combination (AB, AS, DS).
Largescaleofcytotoxicandcytostaticdrugsoﬀersmanyways
toinduceapoptosisorterminaldiﬀerentiationintumorcells.
However, most of them inﬂuence, to some extent, also the
viabilityofnormalcells,andthisfeaturerepresentsunwanted
side eﬀect of cancer therapy. Combined action of more
drugs applied together may minimalize these unadvisable
phenomena by targeting processes speciﬁc for proliferating
(cancer) cells.
DNA-damaging agents, actD and highly concentrated
DAC, belong to the group of very eﬀective, but robust
drugs, whose side eﬀects are signiﬁcant. Histone deacetylase
inhibitors, sodium butyrate and SAHA, are epigenetic drugs
causingmostlyterminaldiﬀerentiationandassuchtheyhave
only small eﬀect on diﬀerentiated, quiescent cells. Increasing
focus on epigenetic mechanism of DAC action when used in
low concentrations gives reason for our intention of further
study of DAC and SAHA combined epigenetic eﬀect.
We investigated the role of ROS in process of cell death
induced by DNA-damaging drugs or by histone deacetylase
inhibitors (HDACis), or by combination of these two types
of drugs. Leukemia cell line CML-T1 (CML) and normal
peripheral blood lymphocytes of healthy donors (PBL) were
studiedtocomparetheeﬀectonproliferatingcellswithfunc-
tionlessapoptoticsignalingandonquiescentcellswithintact
cell death machinery.
At ﬁrst, viability of CML cells treated by drugs in clin-
ically used concentrations for time intervals up to 48h was
tested, and relevant drug concentrations were constituted for
timeframeupto72htoreachcomparableeﬀectsonviability
of PBL. While 8μMD A Ca n d2 m MB U Tc a u s e ds i m i l a r
eﬀect in both cell types, 1μM SAHA and 5nM actD had
to be increased two times to induce similar viability drop
in PBL. Combined treatment with HDACis did not enhance
actD-induced cell death. In parallel, actD-induced markers
ofapoptosis,forexample,p53stabilization,Pumainduction,
or mitochondria depolarization, were not potentiated by the
HDACi presence. From this point of view, there was no
improvement of therapeutic eﬀect of actD alone on CML
but neither side eﬀect was worsened by the combination.
Viability of CML is substantially decreased using SAHA as
potentiating agent for DAC treatment. Unfortunately, SAHA
potentiates DAC action also in lymphocytes. Here, we
suppose the viability drop to be caused predominantly by
nonapoptotic way of the cell death [22]. Considering dif-
ferent concentrations of SAHA used for CML and PBL, we
tested the eﬀect of 1μM SAHA on PBL. Indeed, 1μM SAHA
had no potential to substantially increase the eﬀect of DAC
on viability of normal PBL (data not shown).
As it was described in Introduction, all the drugs tested
are reported to increase the ROS level in some type of
cells, frequently contributing to apoptosis induction. In our
cells, extensive ROS production was detected after HDACi
treatment in both cell types, but the data sets obtained from
diﬀerent lymphocytes donors were much more dispersed
than those from experiments with CML. While moderate
continual increase of ROS production was measured in
actinomycin D-treated PBL too, longer time of action was
necessary to induce the increase of ROS generation by actD
in CML, and this ROS induction was preceded by signiﬁcant
ROS level decrease in 16h interval. Appropriate response
delay was observed also in the viability curve of actD-treated
CML, and this delay did not appear if the cells were treated
by actD in combination with arbitrary histone deacetylase
inhibitor. Moreover, actD + HDACi combined treatment
manifested slightly higher ROS production than HDACi
alone treatment did, irrespective to actD contribution and
the time of action. A signiﬁcant diﬀerence between CML
and PBL we can ﬁnd also in DAC action. While absence ofOxidative Medicine and Cellular Longevity 5
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Figure 2: ROS production induced by actinomycin D (A), sodium butyrate (B), SAHA (S), decitabine (D) or their combination (AB, AS,
DS) in CML cells (a) or PBL (b) during 44h (CML) or 72h (PBL) treatment.
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PARP
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Figure 3: Western blots showing PARP fragmentation and caspase 3 activation during 24h treatment of CML cells (a) or PBL (b). Cells
were treated by actinomycin D (A), sodium butyrate (B), SAHA (S), decitabine (D), or their combination (AB, AS, DS). Symbol C denotes
untreated cells. β-actin expression is showed as a loading control.
any changes in DAC-treated PBL is reﬂected by no eﬀect on
SAHA-induced ROS production in DAC + SAHA combined
treatment, transient decrease of ROS in DAC-treated cells
and extensive ROS generation induced by DAC + SAHA are
observed in CML.
The extent of poly (ADP-ribose) polymerase (PARP)
cleavage serves as a measure of apoptotic eﬀect in cells. In
our cells, PARP fragmentation reﬂects the viability trends
for actD, BUT, DAC, and all combined treatments, but
larger PARP fragmentation occurs also in SAHA-treated
cells.Accordingly,withtheextentofPARPcleavage,extensive
caspase 3 activation was observed in CML treated by actD
and all combinations tested; large caspase 3 activation was
monitored also in SAHA treated cells, but only moderate
eﬀect was detected when BUT or DAC was used to treat
the cells. Surprisingly, only poor or no active caspase 3
fragmentsweredetectedinPBLsamplesbyimmunoblotting.
We detected slight caspase 3 activation in treated PBL by
othermethods—ﬂuorimetricorluminometricmeasurement
of covalently labelled caspase inhibitor cleavage. But while
theamountofactiveexecutivecaspasescontinuallyincreased
in CML during the 48h after drug addition, in PBL transient6 Oxidative Medicine and Cellular Longevity
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Figure 4: Mitochondrial membrane depolarization after 24h
treatment of CML cells or PBL. Cells were treated by actinomycin
D (A), sodium butyrate (B), SAHA (S), decitabine (D), or their
combination (AB, AS, DS). Symbol C denotes untreated cells.
caspase 3 activation in 24h was followed by subsequent
decrease under the control level (data not shown). We
conclude, that in proliferating CML cells, all drugs and
combinationstestedinducedmitochondrialwayofapoptosis
and that ROS production signiﬁcantly assisted in apoptosis
induction. In PBL, large viability drop was accompanied by
appropriate PARP fragmentation, but any signiﬁcant ROS
production changes and executive caspases activation were
not detected during the treatment. This fact conﬁrmed the
thesisthatPARPfragmentationwasnotalwaysdependenton
caspase 3 activation [35] and that other factors were involved
in triggering of this type of PARP cleavage. Therefore, we
c a nc o n c l u d et h a tn e c r o s i sa sw e l la sa p o p t o s i st o o kp a r t
in lymphocytes viability decrease, and this variability is
accompanied also by large deviations in amount of ROS
produced in the treated PBL.
5. Conclusion
In our study, we investigated the role of reactive oxygen
species production during the anticancer drugs treatment of
two types of cells. Diﬀerent DNA-damaging drugs and
histone deacetylase inhibitors were used to treat cancer
or normal cells. We found that in cancer cell line CML-
T1, ROS production signiﬁcantly contributed to apoptosis
triggering, while in normal lymphocytes treated by cytostatic
or cytotoxic drugs, necrosis as well as apoptosis occurred
and large heterogeneity of ROS production was measured.
Combined treatment with histone deacetylase inhibitor did
not potentiate actinomycin D action, whereas combination
of decitabine and SAHA brought synergistic ROS generation
andapoptoticfeaturesinCMLcellline.Appropriatedecrease
of cell viability indicated promising therapeutic potential
of this combination in CML. However, although there was
no synergistic eﬀect in ROS production, the viability drop
of PBL treated by decitabine was also augmented by com-
bination with SAHA denoting that cell death was induced
also in PBL. Further study on both drugs concentrations
optimization is therefore needed to enhance the possibility
to use this combination in cancer therapy.
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